Month: January 2024

Commissioning of Logelbach solar power plant Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the start of production of its Logelbach solar power plant in the Grand-Est region of France with a capacity of 12.1 megawatts Logelbach solar power plant is located in the town of Wintzenheim, on the outskirts to the west of Colmar in the Collectivité Européenne d’Alsace. Built on the former Ligibel landfill site, it now offers a sustainable solution for the renewable energy production by making economic and environmental use of this degaged site. With a capacity of 12.1 megawatts, the Logelbach solar farm covers 12 hectares and has 21,384 solar panels. Annual production is equivalent to the electricity consumption of around 6,000 people. By contributing to France’s energy...

License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License (CDSL) by Health Canada, Canada’s federal health regulator. The CDSL allows PharmAla to offer for sale both 3,4 Methylenedioxymethamphetamine (MDMA) and Psilocybin to those authorized to legally hold these materials. “PharmAla is breaking new ground in the Canadian market. MDMA-Assisted Therapy is still very new – with PharmAla’s...

WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The international conference will take place from January 27 to February 1, 2024 in Maui, Hawaii and covers the latest advancements in wound healing, burn care, and infection control. During this conference, Kane Biotech will present along with other important voices involved in the care of soft tissue injuries and related complications. “I’m excited to be presenting Kane’s revyve™ Antimicrobial Wound Gel to the wound care community at the Boswick conference and believe it will be very well-received, particularly by practitioners focused on burn...

PORTLAND, Maine, Jan. 25, 2024 (GLOBE NEWSWIRE) — Northeast Bank (the “Bank”) (NASDAQ: NBN), a Maine-based full-service bank, announced today it will release its fiscal 2024 second quarter earnings results on Tuesday, January 30, 2024. Following the release, the Bank will host a conference call with a simultaneous webcast at 10:00 a.m. ET on Wednesday, January 31, 2024. The conference call will be hosted by Rick Wayne, President and Chief Executive Officer, JP Lapointe, Chief Financial Officer, and Pat Dignan, Chief Operating Officer. To access the conference call by phone, please go to this link (Phone Registration), and you will be provided with dial in details. The call will be available via a live webcast, which can be viewed by accessing the Bank’s website at www.northeastbank.com and clicking on the Investor Relations section....

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of 01/25/2024MCLEAN, Va., Jan. 25, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.69 percent. “The 30-year fixed-rate has remained within a very narrow range over the last month, settling in at 6.69% this week,” said Sam Khater, Freddie Mac’s Chief Economist. “Given this stabilization in rates, potential homebuyers with affordability concerns have jumped off the fence back into the market. Despite persistent inventory challenges, we anticipate a busier spring homebuying season than 2023, with home prices continuing to increase at a steady pace.” News FactsThe 30-year FRM averaged 6.69 percent as of January 25, 2024,...

Press release        Ecully, January 25, 2024 – 6.00 p.m.2023 revenue of €10.5 millionIn thousands of euros Unaudited data 2023 2022 % changeQ1 revenue 2,399 1,342 +79%Q2 revenue 3,034 1,770 +71%Q3 revenue 2,077 2,249 -8%Q4 revenue 3,009 2,071 +45%Full-year revenue 10,519 7,432* +42%* 2022 revenue includes the share of revenue derived from Spine Innovations since its consolidation on July 21, 2022, i.e. €1.7 million. Spineway recorded revenue of €10.5 million in 2023, an increase of 42% compared with 2022. This growth was driven by the strong sales performance of Distimp products and the consolidation of revenue from Spine Innovations, acquired in July 2022. Europe remains the Group’s leading commercial region (49% of revenue), with 2023 revenue of €5.2 million, up 78% compared with the previous year, thanks to Distimp...

Preliminary consolidated financial results for Kvika banki hf. („Kvika“) for the fourth quarter of 2023 are now available and show that profit before tax for the quarter will amount ISK 1,480 million, which is below management forecast. The results were negatively affected by one-off items amounting to ISK 230 million and an ISK 530 million special impairment of a single domestic loan exposure. In other respects, Kvika‘s operations were in line with outlook during the period. The financial statements for 2023 are preliminary and unaudited and are subject to change until they are published. Kvika will publish its financial results for the year 2023 on 15 February 2024, after markets have closed.Please note that this notice is a disclosure of inside information per article 17 of regulation (EU) No 596/2014 on market abuse (“MAR”),...